Aims: This study assessed variations in pediatric neurosurgical technique when accessing shunts and ventricular access devices (VADs). Methods: A 12-question survey was developed and sent to members of the American Association of Neurological Surgeons (AANS) whose self-identified subspecialty was pediatric neurosurgery. Results: Four hundred and twenty surveys were sent out, and 149 responses were received (35.5% response rate); 95.3% of respondents always use sterile gloves, 55.0% never use a sterile gown, and 69.8% always have a member of the neurosurgery team perform the procedure. The majority of respondents answered “sometimes” for use of a facemask (38.3%), sterile drapes (39.6%), site shaving (45.6%), having an attending present (68.5%), and having an assistant hold the patient's head (78.5%). The majority reported using a 23- or 25-gauge butterfly needle for site entry (96.6%), and betadine or ChloraPrep™ as the preferred antiseptic solution (64.4%). The frequency in which CSF is sent for analysis is not standardized in 31.5% of respondents, and wait time for the antiseptic solution to dry is not standardized in 62.4%. Conclusions: There is great variation in the technique for accessing shunts and VADs. Future studies are needed to assess whether these discrepancies affect infection rates.

1.
Bisno AL, Dickinson GM: In infections associated with indwelling medical devices: infections related to extravascular devices. Antimicrob Agents Chemother 1989;33:602-607.
2.
Stone JJ, Walker CT, Jacobson M, Phillips V, Silberstein HJ: Revision rate of pediatric ventriculoperitoneal shunts after 15 years: clinical article. J Neurosurg Pediatr 2013;11:15-19.
3.
Tröbs RB, Sander V: Posthemorrhagic hydrocephalus in extremely low birth weight infants: Ommaya reservoir vs. ventriculoperitoneal shunt. Childs Nerv Syst 2015;31: 1261-1266.
4.
Mead PA, Safdieh JE, Nizza P, Tuma S, Sepkowitz KA: Ommaya reservoir infections: a 16-year retrospective analysis. J Infect 2014;3:225-230.
5.
Spiegelman L, Asija R, Da Silva SL, Krieger MD, McComb JG: What is the risk of infecting a cerebrospinal fluid-diverting shunt with percutaneous tapping? J Neurosurg Pediatr 2014;14:336-339.
6.
Dawod J, Tager A, Darouiche RO, Al Mohajer M: Prevention and management of internal cerebrospinal fluid shunt infections. J Hosp Infect 2016;93:323-328.
7.
Kestle JR, Garton HJ, Whitehead WE, Drake JM, Kulkarni AV, Cochrane DD, et al: Management of shunt infections: a multicenter pilot study. J Neurosurg 2006;105:177-181.
8.
Morris A, Low DE: Nosocomial bacterial meningitis, including central nervous system shunt infections. Infect Dis Clin North Am 1999;13:735-750.
9.
Sacar S, Turgut H, Toprak S, Cirak B, Coskun E, Yilmaz O, et al: A retrospective study of central nervous system shunt infections diagnosed in a university hospital during a 4-year period. BMC Infect Dis 2006;6:43.
10.
Wu X, Liu Q, Jiang X, Zhang T: Prevention options for ventriculoperitoneal shunt infections: a retrospective analysis during a five-year period. Int J Clin Exp Med 2015;8:19775-19780.
11.
Mechleb B, Khater F, Eid A, David G, Moorman JP: Late onset Ommaya reservoir infection due to Staphylococcus aureus: case report and review of Ommaya infections. J Infect 2003;46:196-198.
12.
Choksey MS, Malik IA: Zero tolerance to shunt infections: can it be achieved? J Neurol Neurosurg Psychiatry 2004;75:87-91.
13.
Kestle JR, Riva-Cambrin J, Wellons JC 3rd, Kulkarni AV, Whitehead WE, Walker ML, et al: A standardized protocol to reduce cerebrospinal fluid shunt infection: the hydrocephalus clinical research network quality improvement initiative. J Neurosurg Pediatr 2011;8:22-29.
14.
Pirotte BJ, Lubansu A, Bruneau M, Loga C, Van Cutsem N, Brotchi J: Sterile surgical technique for shunt placement reduces the shunt infection rate in children: preliminary analysis of a prospective protocol in 115 consecutive procedures. Childs Nerv Syst 2007;23:1251-1261.
15.
Spader HS, Hertzler DA, Kestle JRW, Riva-Cambrin J: Risk factors for infection and the effect of an institutional shunt protocol on the incidence of ventricular access device infections in preterm infants. J Neurosurg Pediatr 2015;15:156-160.
16.
Dinndorf PA, Bleyer WA: Management of infectious complications of intraventricular reservoirs in cancer patients: low incidence and successful treatment without reservoir removal (abstract). Cancer Drug Delivery 2009;4:105-117.
17.
Kormanik K, Praca J, Garton HJ, Sarkar S: Repeated tapping of ventricular reservoir in preterm infants with post-hemorrhagic ventricular dilatation does not increase the risk of reservoir infection. J Perinatol 2010;30:218-21.
18.
Richard E, Cinalli G, Assis D, Pierre-Kahn A, Lacaze-Masmonteil T: Treatment of post-haemorrhage ventricular dilatation with an Ommaya's reservoir: management and outcome of 64 infants. Childs Nerv Syst 2001;17:334-340.
19.
Hudgins RJ, Boydston WR, Gilreath CL: Treatment of posthemorrhagic hydrocephalus in the preterm infant with a ventricular access device. Pediatr Neurosurg 1998;29:309-313.
20.
Schijman E, Steinbok P: International survey on the management of Chiari I malformation and syringomyelia. Childs Nerv Syst 2004;20:341-348.
21.
Haroun RI, Guarnieri M, Meadow JJ, Kraut M, Carson BS: Current opinions for the treatment of syringomyelia and Chiari malformations: survey of the Pediatric Section of the American Association of Neurological Surgeons. Pediatr Neurosurg 2000;33:311-317.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.